Related Experiment Video
Updated: Sep 12, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Vildagliptin and its Association with Bullous Pemphigoid
Ameena Meah1, K Snigdha Reddy1, K A Rajeshwari2
1Internal Medicine, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka, India.
Abstract:
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease usually seen among the elderly and in conditions like stroke and dementia. It has been associated with various trigger factors and has an incidence of 0.2-3 per 1 lakh with an increase in recent times. Out of the various known triggers, drugs play a major role. Gliptins, a common group of antidiabetic medications used for the control of blood glucose levels routinely among type 2 diabetes mellitus patients, have common adverse reactions like headache, weakness, and nausea with rare presentations of skin lesions. We report three cases of elderly diabetics who were on vildagliptin for routine diabetic control, who further developed blistering disease. On evaluation of the skin lesions, a diagnosis of BP was made and confirmed with the help of direct immunofluorescence test. Routine symptomatic management and topical steroids had no role to play in the improvement of symptoms, which led to the suspicion of drug-induced BP. Patients had significantly improved since the discontinuation of vildagliptin with complete resolution over a period. Thus, these case reports help us understand the association of vildagliptin and BP, which was previously not well understood. Considering the prevalence of type 2 diabetes mellitus in India and extensive use of various antidiabetic drugs, complete understanding of adverse reactions helps and guides physicians regarding treatment choices.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

